Professor Georgina Long hands on baton of SMR Presidency
31 October 2020
MIA’s Co-Medical Director, Professor Georgina Long AO, has passed the baton after two years as President of the Society for Melanoma Research (SMR). The US-based SMR is the world’s largest association of melanoma researchers and scientists. Professor Long was the first Australian and first female President of SMR, her election testament to her international standing as one of the world’s pre-eminent melanoma clinicians and researchers.
The annual 2020 SMR Melanoma Congress, scheduled to be held in New Orleans, was postponed due to the impact of COVID-19. Instead, a Virtual Congress was held during which Professor Long handed over the Presidency to Professor Ashani Weeraratna from Johns Hopkins School of Medicine.
In a message to SMR members, Professor Long said, ‘ The COVID-19 pandemic has presented a major challenge for all of us across the world, and we stand united in limiting the impact of the virus on our health, productivity and goals.’
Professor Long cites as a highlight of her 2-year Presidency, the phenomenal research output by SMR members who have continued to lead the cancer field despite the impact of COVID-19.
‘Despite not being able to gather in person, as we usually do annually, we connected virtually from around the world to share our knowledge and continue our collaboration,’ Professor Long said. ‘Importantly, we highlighted the work of two fabulous researchers in the field who both received SMR Awards for their contributions – Stefani Spranger was awarded the Young Investigator Award and Yardena Samuels was awarded the Estela Medrano Award.
‘It has been an honour to lead SMR for the past two years, and I look forward to continued collaboration as we move ever closer to reaching our goal of zero deaths from melanoma,’ she said.
The 2021 Australasian Melanoma Conference (AMC2021) will held in Sydney, Australia.
Drug therapy set to become standard treatment in high-risk early stage patients to stop disease spread
Prof Long AO has been recognised by Australian Academy of Health and Medical Sciences for her transformative work advancing melanoma treatments.
COVID restrictions continue to impact fundraising for melanoma services in Riverina.
Ben Garrow lost his life to melanoma. In his honour his family has established a scholarship to support a PhD student whose work focuses on saving lives from melanoma.
More than 150 clinicians, researchers and MIA staff gathered online to share research highlights.
Independent researchers at The University of Sydney are seeking patient feedback.
A re-cap of the wonderful, and often very creative, community fundraising initiatives over the April to June quarter.
Our patients who donate their tissue samples and records to our research are helping to make a difference to the lives of future melanoma patients.
MIA researchers have recently been awarded two competitive funding grants, which will help facilitate their ground-breaking work in melanoma research.
Celebrate the 10th anniversary of Amie St Clair Melanoma at the Annual Ball in Wagga Wagga!
Postponed to early 2022. Melanoma survivor Matt Kean is doing a 1000km bike ride around the Riverina to increase awareness of melanoma and raise funds for Amie St Clair Melanoma - MIA. There are many ways you can be part of this life-changing ride!
Riverina patients gain access to potentially life saving immunotherapy treatment close to home.
MIA's Prof Scolyer has been appointed as an Officer (AO) of the Order of Australia.
In a breakthrough which could extend to the treatment of other cancers, a new immune checkpoint inhibitor has proven effective in helping save the lives of advanced melanoma patients.
Whilst our research and clinical teams are trialling new treatments to save lives, it is our nurses who are on the front line providing care and support.
The easing of COVID restrictions has meant the return of community events, and we recognise the generous support of our community fundraisers.
Melanoma patients and their carers are being urged to participate in a ground-breaking survey which will shape the future of melanoma treatment, research, support and funding in Australia.